4-Hydroxy-3-methoxymethamphetamine glucuronide as a phase II metabolite of 3,4-methylenedioxymethamphetamine: Enzyme-assisted synthesis and involvement of human hepatic uridine 5′-diphosphate-glucuronosyltransferase 2B15 in the glucuronidation

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 5, 2009, Pages 472-475

  Shoda, Takuji ^a   Fukuhara, Kiyoshi ^a   Goda, Yukihiro ^a   Okuda, Haruhiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

3,4 methylenedioxymethamphetamine; Enzyme assisted synthesis; Glucuronide; Uridine 5 diphosphate glucuronosyltransferase

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE GLUCURONIDE; AMPHETAMINE DERIVATIVE; AROCLOR 1254; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG; URIDINE 5' DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B15;

ANIMAL CELL; ARTICLE; CATALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; GLUCURONIDATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; RAT;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONATES; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; METHAMPHETAMINE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS;

EID: 65949101646     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.472     Document Type: Article

References (17)

1. Nichols D. E., J. Psychoactive Drugs, 18, 305-313 (1986).
2. Strote J., Lee J. E., Wechsler H., J. Adolesc. Health, 30, 64-72 (2002).
3. Schifano F., Oyefeso A., Corkery J., Cobain K., Jambert-Gray R., Martinotti G., Ghodse A. H., Hum. Psychopharmacol., 18, 519-524 (2003).
4. Maurer H. H., Bickeboeller-Friedrich J., Kraemer T., Peters F. T., Toxicol. Lett., 112-113, 133-142 (2000).
5. Lim H. K., Foltz R. L., Chem. Res. Toxicol., 2, 142-143 (1989).
6. de la Torre R., Farre M., Roset P. N., Lopez C. H., Mas M., Ortuno J., Menoyo E., Pizarro N., Segura J., Cami J., Ann. N. Y. Acad. Sci., 914, 225-237 (2000).
7. de la Torre R., Farre M., Roset P. N., Pizarro N., Abanades S., Segura M., Segura J., Cami J., Ther. Drug Monit., 26, 137-144 (2004).
8. Yamada H., Ishii Y., Oguri K., J. Health Sci., 51, 1-7 (2005).
9. Pirnay S. O., Abraham T. T., Lowe R. H., Huestis M. A., J. Anal. Toxicol., 30, 563-569 (2006).
10. Shima N., Kamata H., Katagi M., Tsuchihashi H., Sakuma T., Nemoto N., J. Chromatogr. B, 857, 123-129 (2007).
11. Pizarro N., de la Torre R., Farre M., Segura J., Llebaria A., Joglar J., Bioorg. Med. Chem., 10, 1085-1092 (2002).
12. Morgan P. H., Beckett A. H., Tetrahedron, 31, 2595-2601 (1975).
13. Luukkanen L., Kilpelainen I., Kangas H., Ottoila P., Elovaara E., Taskinen J., Bioconjug. Chem., 10, 150-154 (1999).
14. Fisher M. B., Campanela K., Ackermann B. L., Vandenbrandenn M., Wrighton S. A., Drug Metab. Dispos., 28, 560-566 (2000).
15. Tukey R. H., Strassburg C. P., Annu. Rev. Pharmacol. Toxicol., 40, 581-616 (2000).
16. Green M. D., Oturu E. M., Tephly T. R., Drug Metab. Dispos., 22, 799-805 (1994).
17. Court M. H., Hao Q., Krishnaswamy S., Bekaii-Saab T., Al-Rohaimi A., von Moltke L. L., Greenblatt D. J., J. Pharmacol. Exp. Ther., 310, 656-665 (2004).